Ligend M 500 

Presentation: Each film-coated tablet contains Linagliptin INN 2.5 mg and Metformin Hydrochloride BP 500 mg. Available in strips.

Indications: Ligend M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

Dosage and Administration: The dosage should be individualized based on the patient's current regimen, glycemic control, and tolerability, not exceeding the maximum recommended daily dose of linagliptin 5 mg and metformin 2000 mg. The usual starting dose in patients not currently treated with metformin is one tablet twice daily with meals. In patients already on metformin, the starting dose is one tablet of Ligend M 500 twice daily, providing the same daily dose of metformin. Swallow whole with water; do not crush or chew. Dose escalation should be gradual to reduce gastrointestinal side effects associated with metformin.

Side Effects: Common side effects may include diarrhea, nausea, vomiting, and headache. Hypoglycemia may occur when used in combination with insulin or sulfonylureas. Other possible side effects include nasopharyngitis.

Precautions: Contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute metabolic acidosis, diabetic ketoacidosis, and known hypersensitivity to linagliptin or metformin. Use with caution in patients with moderate renal impairment, history of pancreatitis, and heart failure. Avoid excessive alcohol intake.

Storage: Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.